1592U89
National Institutes of Health
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Abacavir (1592U89, or Ziagen) is a powerful and selective inhibitor of HIV-1 viral replication that has been approved by the FDA…
Objectives. To evaluate the pharmacokinetic features, safety, and tolerance of abacavir, given alone and in combination with…
ABSTRACT The use of combinations of anti-human immunodeficiency virus (anti-HIV) agents targeted to different molecular targets…
L'invention concerne des combinaisons therapeutiques de (-)-(1S, 4R)-4-[2-amino-6- (cyclopropylamino)-9H-purin-9-yl] -2…
Gilead Sciences is removing the CD-4 and viral load requirements for people to enter its expanded access program for adefovir…
Early studies of 1592U89 (abacavir), a new nucleoside analog, suggest that it may have the strongest anti-HIV effect of any…
The invention relates to combinations THERAPEUTIC [3R * (1R *, 2S *)] - [3 - [[(4-aminophenyl) SULF ONIL] (2-methylpropyl) -amino…
A number of AIDS clinical trials group studies are investigating the prevention of perinatal HIV transmission (PHT) using…
(57) Abstract: The present invention has an anti-HIV activity (1S, 4R) - cis -4- [2-amino-6- (cyclopropylamino) -9H- purin-9-yl…
L'invention concerne des combinaisons therapeutiques de (1S,4R)-cis-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene…